Combined therapy with deferiprone and desferrioxamine in thalassemia major

Haematologica

Volumn 90, Issue 10, 2005, Pages 1309-1314

  Origa, Raffaella ^a   Bina, Patrizio ^b   Agus, Annalisa ^a   Crobu, Gabriella ^a   Defraia, Elisabetta ^a   Dessì, Carlo ^a   Leoni, Giovan Battista ^a   Muroni, Pier Paolo ^a   Galanello, Renzo ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Osp Regionale per le Microcitemie   (Italy)

Author keywords

Combined therapy; Deferiprone; Desferrioxamine; Iron overload; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGRANULOCYTOSIS; ARTHRALGIA; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; EVALUATION; FEMALE; FERRITIN BLOOD LEVEL; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PATIENT; THALASSEMIA MAJOR; URINARY EXCRETION; VOMITING;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; BETA-THALASSEMIA; CARDIOVASCULAR DISEASES; CHILD; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PYRIDONES;

EID: 27144560152     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Brittenham GM. The red cell cycle. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron metabolism in health and disease, WB Saunders Co, London, 1994.
2. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36.
3. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89: 1187-93.
5. Modell B, Khan M, Darlison M. Survival in β thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2
6. Cunningham J, Macklin EA, Neufeld EJ, Cohen A, Thalassemia Clinical Research Network. Complications of thalassemia major in North America. Blood 2004; 104:34-9.
7. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1-2-dimethyl-3-hydroxypyrid-4-1, an orally active chelator for treatment of iron overload. Lancet 1987;1:1294-5.
8. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, et al. Effective chelation of iron in beta thalassemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-1. Br Med J 1987;295:1509-12.
9. Cohen A, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583-7.
10. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102:17-24.
11. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103: 361-4.
12. Balveer K, Pryor K, Wonke B. Combined oral and parenteral iron chelation in β thalassemia major. Med J Malaysia 2001; 55:493-7.
13. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003;121:187-9.
14. Athanassiou-Metaxa M, Kousi A, Hatzipantelis ES, Tsatra I, Ikonomou M, Perifanis V, et al. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients. Haematologica 2004; 89:ELT07.
15. Farmaki K, Anagnostopoulos G, Platis O, Gotsis E, Toulas P. Combined chelation therapy in patients with thalassemia major: a fast and effective method of reducing ferritin levels and cardiological complications Hematol J 2002; 3 Suppl 1:79 [abstract].
16. Alymara V, Bourantas DK, Chaidos A, Hatzimichael EC, Verges A, Dimos GA et al. Combined iron chelation therapy with desferrioxamine and deferiprone in beta-thalassemic patients. Hematol J 2002;3 Suppl 1:81 [abstract].
17. Kattamis, Kassou C, Ladis V, Berdussi H, Papasotiriou I, Kattamis C. Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia. Blood 2002; 100:120a[abstract].
18. th International Conference on Oral Chelation in the Treatment of Thalassaemia Major and Other Diseases: Catania, Italy; 2001. p. 74-8 [abstract].
19. Cohen AR, Galanello R, Piga A, Di Palma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol 2000;108: 305-12.
20. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 2003;101:91-6.
21. Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan, M, Olivieri NF, Tondury P, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995;91:224-9.
22. Berkovitch M, Laxer R, Inman R, Koren G, Pritzker KP, Fritzler MJ, et al. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994; 343: 1471-2.
23. Breuer W, Ermers MJJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 2001;97:792-8.
24. Al-Refaie FN, Wonke B, Wickens DG, Aydinok Y, Fielding A, Hoffbrand AV. Zinc concentration in patients with iron overload receiving iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 or deferoxamine J Clin Pathol 1994;343:1471-2.
25. Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Safety 1992;7 Suppl 1:17-25.
26. Olivieri NF, Brittenham GM, Armstrong SAM, Basran, RK, Daneman, R, Daneman N, et al. First prospective randomized trials of the iron chelators deferiprone (L1) and deferoxamine. Blood 1995; 86:249 [abstract].
27. Anderson LJ, Wonke N, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360:516-20.
28. Piga A, Gaglioti C, Fogliaccio E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-96
29. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia. Blood 2000;95:1229-36.
30. th International Conference on Thalassemia and Hemoglobinopathies; Palermo 15-19 October 2003.